An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...

Tirzepatide improves kidney function and cardiovascular outcomes in patients with obesity and heart failure with preserved ejection fraction (HFpEF), regardless of chronic kidney disease status.

Get Instant Summarized Text (Gist) A natural mechanism that protects against heart failure with preserved ejection fraction (HFpEF) has been identified. When this mechanism fails, it leads to ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

At one year, patients taking tirzepatide had a 38% lower rate of cardiovascular death or worsening heart failure (defined as worsening heart failure symptoms in addition to hospitalization or the ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Whereas obesity is a common confounder when interpreting natriuretic peptide values, and the presence of atrial fibrillation has an important influence on pretest probability, other confounders are ...

The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction,” published in the March 2025 issue of the ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year ...